StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by polo11on Dec 03, 2016 1:19pm

80 Views

Post# 25550676

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:how much will PP be ?

Please give us 5 example within 20 min if so many

thepbay wrote: Polo, my point is that with everything in the pipe, and all the expectations GEN has in a very short term, or so they say, they should have been able to get a much higher premium. The broker working the deal set this price so they could sell the proposal. I have seen many debentures where they have gotten above 60% premium. I would have expected something similar here. They got an average deal, nothing to hype up. It is however better that all their previous options. Give to get I guess. GL

pbay